睿昂基因收盘上涨2.50%，最新市净率1.28，总市值11.67亿元

Core Viewpoint - Ruiang Gene's stock closed at 20.89 yuan, up 2.50%, with a market-to-book ratio of 1.28 and a total market value of 1.167 billion yuan [1] Company Overview - Ruiang Gene specializes in the research, production, sales, and scientific services of in vitro diagnostic products, with key products including leukemia-related fusion gene testing kits and various gene mutation testing kits [1] - As of December 31, 2024, the company holds 114 medical device products approved or registered by the National Medical Products Administration, including 31 Class III medical device registration products [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while net profit reached 3.355 million yuan, a significant increase of 529.26%, with a sales gross margin of 71.00% [2] - The company's price-to-earnings (P/E) ratio (TTM) is -90.15, and the price-to-book (P/B) ratio is 1.28, with a total market value of 1.167 billion yuan [2]